dextran

Small moleculeexperimental

Dextran 70 is a type of fluid given by injection into a vein to expand blood volume. Specifically it is used for shock such as that caused by bleeding or burns when blood transfusions are not quickly available. However, it does not carry oxygen. — Wikipedia

Chemistry & pharmacology

Loading structure…

SMILES

O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O
Mol. weight
504.44 g/mol
Lipinski Ro5
3 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • aquasite
  • dextran
  • dextran
  • dextran
  • dextran 40
  • dextran 40
  • dextran 40
  • dextran 70
  • dextran 70
  • dextran 70
  • dextran 70
  • dextran sulfate
  • dextran sulfate sodium
  • infukoll
  • low molecular weight sulfated dextran

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04944901Phase 1Aug 3, 2021Scioto Biosciences, Inc., University of Cincinnati
NCT05266690N/ANov 29, 2019Nestle
NCT03867851Phase 2Apr 15, 2019TikoMed AB
NCT03705390Phase 2Mar 29, 2019Neuregenix, TikoMed AB, University of Birmingham
NCT03613571Phase 2Aug 15, 2018TikoMed AB
NCT03934073N/AFeb 2, 2018Centre Hospitalier St Anne
NCT02863809Phase 1/Phase 2 (Phase 2)Mar 15, 2017Department of Defense, Harvard University
NCT03070353Phase 2/Phase 3 (Phase 3)Jul 1, 2015Mahidol University
NCT02507362Phase 1/Phase 2 (Phase 2)Aug 1, 2014Isfahan University, University of Tehran
NCT01732757Phase 4Nov 1, 2012Allergan
NCT01470118Phase 4Oct 1, 2011Allergan
NCT01978015Phase 4Oct 1, 2011University of Campinas
NCT01282138Phase 4Dec 1, 2010Alcon
NCT00789308Phase 2Jul 1, 2008Karolinska Institute, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Uppsala University
NCT00790439Phase 2Jul 1, 2008National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Uppsala University
NCT00698724Phase 4Jun 1, 2008Bp Consulting, Inc
NCT00570960Phase 4Jun 1, 2007American Association for the Study of Liver Diseases, University of Virginia
NCT00266838Phase 1Jul 1, 2006Katholieke Universiteit Leuven
NCT00878631Phase 2/Phase 3 (Phase 3)Sep 1, 2004Defence Research and Development Canada, University of Toronto
NCT01642524Phase 3Apr 1, 2004Defence Research and Development Canada, University of Toronto
Showing 20 of 26 trials
Page 1 / 2

Organizations

Research & Development (30)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institute of Allergy and Infectious Diseases (NIAID)Government5531999
TikoMed ABFor profit3212018
AllerganFor profit2212011
Defence Research and Development CanadaGovernment2012004
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government2012008
University of TorontoAcademic/Hospital2212004
Uppsala UniversityAcademic/Hospital2012008
AlconFor profit1112010
American Association for the Study of Liver DiseasesAcademic/Hospital1012007
BioPhausiaFor profit1012003
Bp Consulting, IncFor profit1112008
Centre Hospitalier St AnneAcademic/Hospital1112018
Department of DefenseGovernment1012017
Harvard UniversityAcademic/Hospital1112017
Isfahan UniversityAcademic/Hospital1112014
Karolinska InstituteAcademic/Hospital1012008
Katholieke Universiteit LeuvenAcademic/Hospital1112006
Mahidol UniversityAcademic/Hospital1112015
National Heart, Lung, and Blood Institute (NHLBI)Government1012003
NestleFor profit1112019
30 organizations
Page 1 / 2